论文部分内容阅读
目的观察辛伐他汀对心肌梗死后无症状心衰(silent heart failure,SHF)患者氨基末端脑钠肽前体(NT-proBNP)、心室重构的影响。方法 90例陈旧性前壁心肌梗死患者(NYHAⅠ级)在常规治疗基础上加服辛伐他汀,43例服辛伐他汀12个月设为观察组,47例1个月内停服辛伐他汀设为对照组,比较两组治疗前一般资料、治疗前和治疗12个月后血浆NT-proBNP左室重构及功能相关指标的变化结果两组治疗后血浆NT-proBNP水平均较治疗前显著降低(P<0.05),治疗后观察组血浆NT-proBNP水平显著低于对照组(P<0.05)。治疗后,两组左室质量指数(LVMI)、左室舒张末期内径(LVEDD)、舒张末左室后壁厚度(LVPWT)较治疗前均显著降(P<0.01),观察组LVMI、LVPWT显著小于对照组(P<0.01);两组舒张末室间隔厚度(IVST)、左室短轴缩短率(FS)较治疗前均显著增加(P<0.01),观察组IVST、FS显著大于对照组(P<0.01)。结论常规治疗基础上加用辛伐他汀能进一步改善心肌梗死后无症状心衰患者心功能并减轻心室重构,延缓临床心衰的发生。
Objective To observe the effect of simvastatin on the levels of NT-proBNP and ventricular remodeling in patients with silent heart failure (SHF) after myocardial infarction. Methods Ninety patients with old AMI (NYHA class Ⅰ) were given simvastatin on the basis of routine treatment, 43 were given simvastatin for 12 months as observation group, and 47 patients were given simvastatin within one month As the control group, comparing the two groups before treatment information, plasma NT-proBNP left ventricular remodeling and function-related index changes before and 12 months after treatment Results Plasma NT-proBNP levels after treatment in both groups were significantly higher than before treatment (P <0.05). After treatment, the plasma NT-proBNP level in the observation group was significantly lower than that in the control group (P <0.05). After treatment, LVMI, LVEDD and LVPWT in both groups were significantly lower than those before treatment (P <0.01), LVMI and LVPWT in the observation group were significantly lower than those before treatment (P <0.01). The IVST and FS of both groups were significantly higher than those before treatment (P <0.01). The IVST and FS of the observation group were significantly higher than those of the control group (P <0.01). Conclusion The addition of simvastatin to conventional treatment can further improve the cardiac function, alleviate the cardiac remodeling and delay the occurrence of clinical heart failure in patients with asymptomatic heart failure after myocardial infarction.